Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: A Cochrane review

HPB

Volumn 12, Issue 3, 2010, Pages 155-165

  Koti, Rahul S ^a   Gurusamy, Kurinchi S ^a   Fusai, Giuseppe ^a   Davidson, Brian R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Octreotide; Pancreatic fistula; Pancreatic resection; Somatostatin; Systematic review

Indexed keywords

OCTREOTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; VAPREOTIDE; GASTROINTESTINAL AGENT;

ANASTOMOSIS LEAKAGE; BLEEDING; CHRONIC PANCREATITIS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; LUNG DISEASE; META ANALYSIS; MORTALITY; PANCREAS FISTULA; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PANCREATITIS; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; REOPERATION; REVIEW; SYSTEMATIC REVIEW; PANCREAS; PANCREAS RESECTION; PANCREATIC DISEASES; PANCREATIC FISTULA; POSTOPERATIVE COMPLICATIONS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS;

GASTROINTESTINAL AGENTS; HUMANS; LENGTH OF STAY; OCTREOTIDE; PANCREAS; PANCREATECTOMY; PANCREATIC DISEASES; PANCREATIC FISTULA; PANCREATICODUODENECTOMY; POSTOPERATIVE COMPLICATIONS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SOMATOSTATIN;

EID: 77953574239     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00157.x     Document Type: Review

References (39)

1. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. (2004) Current standards of surgery for pancreatic cancer. Br J Surg 91:1410-1427.
2. Gouma DJ, van Geenen RC, van Gulik TM, de Haan RJ, de Wit LT, Busch OR et al. (2000) Rates of complications and death after pancreati-coduodenectomy: risk factors and the impact of hospital volume. Ann Surg 232:786-795.
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA et al. (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579.
4. Connor S, Alexakis N, Garden OJ, Leandros E, Bramis J, Wigmore SJ. (2005) Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 92:1059-1067.
5. Harris AG. (1994) Somatostatin and somatostatin analogues: pharmaco-kinetics and pharmacodynamic effects. Gut 35 (Suppl. 3):1-4.
6. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. (1987) Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36:108-124.
7. Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM, Flamant Y et al. (2004) Octreotide in the prevention of intra-abdominal complications following elective pancreatic resection: a prospective, multicentre randomized controlled trial. Arch Surg 139:288-294.
8. Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ et al. (1995) Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 82:1270-1273.
9. Sarr MG. (2003) The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatec-tomy: a prospective, multicentre, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 196:556-564.
10. Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA et al. (2000) Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 232:419-429.
11. Forman D, Delaney B, Kuipers E, Malthaner R, Moayyedi P, Gardener E et al. (2009) Cochrane Upper Gastrointestinal and Pancreatic Diseases Group. About The Cochrane Collaboration (Cochrane Review Groups [CRGs]) 1: Art. No.: UPPERGI
12. Royle P, Milne R. (2003) Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. Int J Technol Assess Health Care 19:591-603.
13. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J et al. (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138:8-13.
14. Kjaergard LL, Villumsen J, Gluud C. (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982-989.
15. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M et al. (1998) Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609-613.
16. Schulz KF, Chalmers I, Hayes RJ, Altman DG. (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412.
17. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al. (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336:601-605.
18. Higgins JPT, Green S. (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. Cochrane Collaboration. [Accessed 10 October 2009.]
19. Gurusamy KS, Gluud C, Nikolova D, Davidson BR. (2009) Assessment of risk of bias in randomized clinical trials in surgery. Br J Surg 96:342-349.
20. DerSimonian R, Laird N. (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
21. DeMets DL. (1987) Methods for combining randomized clinical trials: strengths and limitations. Stat Med 6:341-350.
22. Newell DJ. (1992) Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 21:837-841.
23. Higgins JP, Thompson SG. (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
24. Egger M, Davey SG, Schneider M, Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
25. Macaskill P, Walter SD, Irwig L. (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20:641-654.
26. Kollmar O, Moussavian MR, Richter S, de RP, Maurer CA, Schilling MK. (2008) Prophylactic octreotide and delayed gastric emptying after pan-creaticoduodenectomy: results of a prospective randomized double-blinded placebo-controlled trial. Eur J Surg Oncol 34:868-875.
27. Gouillat C, Chipponi J, Baulieux J, Partensky C, Saric J, Gayet B. (2001) Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 88:1456-1462.
28. Shan YS, Sy ED, Tsai ML, Tang LY, Li PS, Lin PW. (2005) Effects of somatostatin prophylaxis after pylorus-preserving pancreaticoduodenec-tomy: increased delayed gastric emptying and reduced plasma motilin. World J Surg 29:1319-1324.
29. Tulassay Z, Flautner L, Sandor Z, Fehervari I. (1993) Perioperative use of somatostatin in pancreatic surgery. Acta Biomed Ateneo Parmense 64:205-211.
30. Klempa I, Baca I, Menzel J, Schuszdiarra V. (1991) [Effect of somatostatin on basal and stimulated exocrine pancreatic secretion after partial duode-nopancreatectomy. A clinical experimental study.] Chirurg 62:293-299.
31. Beguiristain A, Espi A, Balen E, Pardo F, Hernandez Lizoain JL, Alvarez CJ. (1995) [Somatostatin prophylaxis following cephalic duodenopancre-atectomy.] Rev Esp Enferm Dig 87:221-224.
32. Buccoliero F, Pansini GC, Mascoli F, Mari C, Donini A, Navarra G. (1992) [Somatostatin in duodenocephalopancreatectomy for neoplastic pathology.] Minerva Chir 47:713-716.
33. Hesse UJ, Decker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P et al. (2005) Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. World J Surg 29:1325-1328.
34. Buchler M, Friess H, Klempa I, Hermanek P, Sulkowski U, Becker H et al. (1992) Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 163:125-130.
35. Lange JR, Steinberg SM, Doherty GM, Langstein HN, White DE, Shawker TH et al. (1992) A randomized, prospective trial of postoperative soma-tostatin analogue in patients with neuroendocrine tumours of the pancreas. Surgery 112:1033-1037.
36. Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G et al. (1995) Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 117:26-31.
37. Pederzoli P, Bassi C, Falconi M, Camboni MG. (1994) Efficacy of oct-reotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 81:265-269.
38. Briceno Delgado FJ, Lopez CP, Rufian PS, Solorzano PG, Mino FG, Pera MC. (1998) [Prospective and randomized study on the usefulness of octreotide in the prevention of complications after cephalic duodeno-pancreatectomy.] Rev Esp Enferm Dig 90:687-694.
39. Sweeting MJ, Sutton AJ, Lambert PC. (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23:1351-1375.